I5036
Isocitrate Dehydrogenase 1 (NADP+) human
recombinant, expressed in E. coli, lyophilized powder, ≥80 units/mg protein
Synonym(s):
IDH1, Isocitrate Dehydrogenase Cytoplasmic
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
Recommended Products
recombinant
expressed in E. coli
Quality Level
Assay
≥90% (SDS-PAGE)
form
lyophilized powder
specific activity
≥80 units/mg protein
mol wt
46,658 Da
storage temp.
−20°C
Looking for similar products? Visit Product Comparison Guide
General description
Isocitrate dehydrogenase 1 (IDH1) gene is located on human chromosome 2q33. IDH1 is present in the cytoplasm and peroxisomes. It is expressed at high levels in the mammalian liver. IDH1 consists of a C-terminal tripeptide peroxisome, that targets the signal one sequence.
Biochem/physiol Actions
Isocitrate dehydrogenase 1 (IDH1) help in the oxidative carboxylation of isocitrate to α-ketoglutarate, that results in the formation of reduced nicotinamide adenine dinucleotide phosphate (NADPH). It participates in lipid metabolism and glucose sensing. Suppressing IDH1 in pancreatic islets affects the insulin secretion, induced by glucose and leads to increase in lactate production.
Unit Definition
One unit corresponds to the amount of enzyme which converts 1.0 μmol DL-isocitrate to α-ketoglutarate per minute at pH 7.4 and 37 °C (NADP as cofactor).
Physical form
Supplied as a lyophilized powder containing Tris-HCl pH 8.0, trehalose, ammonium sulfate and DTT
Storage Class Code
11 - Combustible Solids
WGK
WGK 2
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas
Sanson M, et al.
Journal of Clinical Oncology, 27(25), 4150-4154 (2009)
Mast cell tryptase and carboxypeptidase A expression in body fluid and gastrointestinal tract associated with drug-related fatal anaphylaxis
Guo X J, et al.
World Journal of Gastroenterology, 21(47), 13288-13288 (2015)
Paola Guglielmelli et al.
Blood, 123(14), 2157-2160 (2014-01-25)
The JAK1/JAK2 inhibitor ruxolitinib produced significant reductions in splenomegaly and symptomatic burden and improved survival in patients with myelofibrosis (MF), irrespective of their JAK2 mutation status, in 2 phase III studies against placebo (COMFORT-I) and best available therapy (COMFORT-II). We
Chien-Chin Lin et al.
American journal of hematology, 89(2), 137-144 (2013-10-12)
Current information about clinical significance of IDH mutations in myelodysplastic syndromes (MDS), their association with other genetic alterations and the stability during disease progression is limited. In this study, IDH mutations were identified in 4.6% of 477 patients with MDS
Chuan-Bao Zhang et al.
Journal of cancer research and clinical oncology, 140(1), 45-51 (2013-10-24)
Isocitrate dehydrogenase (IDH) gene mutation is one of the most exciting new advances in these years. It has been reported that IDH gene frequently altered in grade II and grade III gliomas. We aimed to identify the mutation frequency of
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service